Literature DB >> 32278463

Contemporary Trends in Native Valve Infective Endocarditis in United States (from the National Inpatient Sample Database).

Muhammad Zia Khan1, Muhammad Bilal Munir2, Muhammad U Khan3, Safi U Khan3, Mina M Benjamin3, Sudarshan Balla4.   

Abstract

Infective Endocarditis (IE) is associated with high mortality and morbidity. The data on contemporary trends and health care utilization remain scarce for IE. Consequently, we used the National Inpatient Sample database from 2002 to 2016 to study burden of IE. Risk-adjusted rates were calculated using an Analysis of Covariance with the Generalized Linear Model. Trends were assessed with linear regression and Pearson's Chi-square modeling, where appropriate. Binomial logistic regression was used for computing predictors of in-hospital mortality. We identified 523,432 hospitalizations for native valve IE. Risk-adjusted mortality decreased from 16.7% in 2002 to 9.7% in 2016 (p <0.01). The risk-adjusted length of stay decreased from 17.4 days in 2002 to 13.4 days in 2016 (p <0.01). Mean cost of stay adjusted for risk factors and inflation increased from 112,702$ in 2002 to 164,767$ in 2016 (p <0.01). Valve replacement increased from 10.2% in 2002 in to 13.4% in 2016, (p <0.01). Independent predictors of mortality included age (OR, 1.02 [1.02 to 1.020], p <0.01), female gender (OR, 1.07 [1.05 to 1.09], p <0.01), Blacks (OR, 1.28 [1.24 to 1.31], p <0.01), Hispanics (OR, 1.15 [1.11 to 1.19], p <0.01) and patients with co-morbid conditions like congestive heart failure (OR, 1.78 [1.74 to 1.82], p <0.01), renal failure (OR, [1.69 [1.65 to 1.73], p <0.01) and weight loss (OR, 1.40 [1.36 to 1.43], p <0.01). In summary, in-hospital mortality from native valve IE has been decreasing but total hospitalization and average cost of stay has increased.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32278463      PMCID: PMC7439520          DOI: 10.1016/j.amjcard.2020.02.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

Review 1.  Management of infective endocarditis: challenges and perspectives.

Authors:  Franck Thuny; Dominique Grisoli; Frederic Collart; Gilbert Habib; Didier Raoult
Journal:  Lancet       Date:  2012-02-07       Impact factor: 79.321

2.  Adherence to Methodological Standards in Research Using the National Inpatient Sample.

Authors:  Rohan Khera; Suveen Angraal; Tyler Couch; John W Welsh; Brahmajee K Nallamothu; Saket Girotra; Paul S Chan; Harlan M Krumholz
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

Review 3.  2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: Executive summary.

Authors:  Gösta B Pettersson; Joseph S Coselli; Gösta B Pettersson; Joseph S Coselli; Syed T Hussain; Brian Griffin; Eugene H Blackstone; Steven M Gordon; Scott A LeMaire; Laila E Woc-Colburn
Journal:  J Thorac Cardiovasc Surg       Date:  2017-01-24       Impact factor: 5.209

Review 4.  Practical Guide to Surgical Data Sets: Healthcare Cost and Utilization Project National Inpatient Sample (NIS).

Authors:  Jonah J Stulberg; Elliott R Haut
Journal:  JAMA Surg       Date:  2018-06-01       Impact factor: 14.766

5.  Profile of infective endocarditis at a tertiary-care hospital in Japan over a 14-year period: characteristics, outcome and predictors for in-hospital mortality.

Authors:  Ryota Hase; Yoshihito Otsuka; Kazuki Yoshida; Naoto Hosokawa
Journal:  Int J Infect Dis       Date:  2015-01-07       Impact factor: 3.623

6.  Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015.

Authors:  Aaron T Fleischauer; Laura Ruhl; Sarah Rhea; Erin Barnes
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-06-09       Impact factor: 17.586

7.  The associations between socioeconomic status and risk of Staphylococcus aureus bacteremia and subsequent endocarditis - a Danish nationwide cohort study.

Authors:  Louise Bruun Oestergaard; Michelle D Schmiegelow; Niels Eske Bruun; Robert L Skov; Andreas Petersen; Paal Skytt Andersen; Christian Torp-Pedersen
Journal:  BMC Infect Dis       Date:  2017-08-25       Impact factor: 3.090

8.  Increasing incidence of IV-drug use associated endocarditis in southern West Virginia and potential economic impact.

Authors:  Mark C Bates; Frank Annie; Ayan Jha; Fred Kerns
Journal:  Clin Cardiol       Date:  2019-03-14       Impact factor: 2.882

9.  Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: The need to expand substance use disorder treatment and harm reduction services.

Authors:  Kinna Thakarar; Kristina E Rokas; F L Lucas; Spencer Powers; Elizabeth Andrews; Christina DeMatteo; Deirdre Mooney; Marcella H Sorg; August Valenti; Mylan Cohen
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

10.  Infective endocarditis in the U.S., 1998-2009: a nationwide study.

Authors:  David H Bor; Steffie Woolhandler; Rachel Nardin; John Brusch; David U Himmelstein
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  3 in total

1.  Clinical outcomes in patients with native valve infective endocarditis and diabetes mellitus.

Authors:  Temidayo Abe; Harry Onoriode Eyituoyo; Gabrielle De Allie; Titilope Olanipekun; Valery Sammah Effoe; Kikelomo Olaosebikan; Paul Mather
Journal:  World J Cardiol       Date:  2021-01-26

2.  Infective Endocarditis: Still More Challenges Than Convictions.

Authors:  Catarina Sousa; Fausto J Pinto
Journal:  Arq Bras Cardiol       Date:  2022-05       Impact factor: 2.667

3.  Different drugs, different sides: injection use of opioids alone, and not stimulants alone, predisposes to right-sided endocarditis.

Authors:  Rochelle Johnstone; Nadine Khalil; Esfandiar Shojaei; Klajdi Puka; Lise Bondy; Sharon Koivu; Michael Silverman
Journal:  Open Heart       Date:  2022-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.